Optimizing Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

复发性或难治性弥漫性大 B 细胞淋巴瘤的优化治疗

• 批准号: 364465
• 负责人: Geoffrion Dominique
• 金额: $ 0.36万
• 依托单位: Lady Davis Institute for Medical Research (Mtl)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2017-05-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=364465&lang=en
• 关键词: Cd20 Antigen; Dlbcl; Immunohistochemistry; Mutation; P53; R-Chop; Whole Exome Sequencing

Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) will relapse after a frontline chemotherapy (RCHOP). Only 10% with relapsed or refractory DLBCL (rrDLBCL) are cured with second line chemotherapy followed by autologous stem cell tra

大约50%的弥漫性大B细胞淋巴瘤（DLBCL）患者在一线化疗（RCHOP）后会复发。只有10%的复发性或难治性DLBCL（rrDLBCL）患者通过二线化疗后接受自体干细胞移植治愈。